Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

vention Center 12-Month Efficacy and Tolerability of MTS in Children with ADHD marion.glick@porternovelli.com jennifer.anello@porternovelli.com

Frank A. Lopez, MD; Oscar G. Bukstein, MD; Robert L. Findling, MD; John M. Turnbow, MD; Liza Squires, MD

Children's Developmental Center, Maitland, FL; Western Psychiatric Institute and Clinic, Pittsburgh, PA; University Hospitals of Cleveland, Cleveland, OH; Westex Clinical Investigations, Lubbock, TX; Shire US Inc., Wayne, PA

About DAYTRANA

DAYTRANA should not be used in patients with allergy to methylphenidate or patch components; marked anxiety, tension and agitation; glaucoma; tics, diagnosis or a family history of Tourette's syndrome; seizures; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam, to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Growth and hematologic monitoring is advised during prolonged treatment. P
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:6/19/2013)... 19, 2013  Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... number one overall pharmacy equipment vendor in the ... a leading independent healthcare research firm, compared the ... its annual rankings. Omnicell also received the prestigious ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
Breaking Medicine Technology:Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS ... developer, manufacturer and seller of medicine and drugs ... announced that it plans to sell or transfer ... in the Chahaer Industrial Park, Inner Mongolia. Lotus, ...
... Inc. (OTC Bulletin Board: BHRT ) announced ... it finalized the formation of a working group. The ... clinical trial, combining a left ventricle assist device (LVAD) ... Bioheart,s MyoCath needle tipped catheter delivery system.   Initial ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia 2Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 2Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 3Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 4Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 5
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common on ... than others to "hook up"? A new study ... Behavioral and Preventive Medicine, published online by the ... are certain factors and behaviors associated with sexual ... "Given the potential for negative emotional and physical ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... at Moffitt Cancer Center and colleagues at Louisiana State ... cancers that require immediate therapy. It relies on understanding ... goal is to better predict a prostate cancer,s aggressiveness ... was published in the online journal PLOS ONE ... cancer accounts for 20 percent of all cancers and ...
(Date:6/19/2013)... 19, 2013 Alternatives, a revolutionary new ... to quit using drugs while allowing them to continue ... founders of Alternatives, believe that abstinence-only approaches force people ... treatment and that this approach hurts instead of helping. ... the United States need treatment for addiction but only ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... choosing a partner, women believe the lower the man,s voice, ... a woman with a higher voice is more likely to ... the latest edition of the online journal Evolutionary Psychology ... pitch and perceived infidelity and offers insight into the evolution ...
... Osteoarthritis - the most influential European bone meeting ... ,Palacio de Congresos, from March 23-26, 2011:,Register before ... of lower registration fees. Listen to ... Learn about key topics in 12 Meet-the-Professor Sessions, Take ...
... The combined effects of chemotherapy and endocrine therapy ... cancer survivors. In a study scheduled for publication in ... Medicine and Rehabilitation , researchers from the Oregon Health ... breast cancer survivors whether they had fallen in the ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) -- More ... than men are engaging in same-sex encounters, according to a ... In statistics compiled from interviews with 13,500 men and women ... Growth also indicates that more than half of young people ...
... (HealthDay News) -- Bunions, a common but painful deformity of the ... a new study has found. And the more severe the ... other parts of the body, leading to declines in both general ... is a bump that develops on the side of the big ...
... March 3, 2011 Unexpected results from a Scripps ... ideas about Alzheimer,s diseasepointing to the liver instead of the ... as brain plaques associated with this devastating condition. The findings ... treatment. The study was published online today in ...
Cached Medicine News:Health News:Can you predict your mate will cheat by their voice? 2Health News:Breast cancer survivors at higher risk for falls 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 2Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 4
PremierEdge Stab Knives - 30....
... for the total eye. Whether used ... mode or set independently to accommodate ... settings are adjustable to accommodate maximizing ... for use with tonometer-mounted, hand-held and ...
PremierEdge™ MVR Knives. Angled....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Medicine Products: